Pfizer Inc. has completed the sale of its remaining 7.3% stake in Haleon Plc, generating about £2.55 billion ($3.3 billion) in proceeds. The pharmaceutical company offered around 618 million shares to investors at a price of £3.85 per share, which was a slight discount compared to Haleon's closing price. The demand for the shares exceeded the offering size, indicating strong investor interest. Additionally, Pfizer also conducted an off-market share repurchase transaction with Haleon, selling approximately £170 million worth of shares back to the company.

Haleon was established in 2022 following the merger of GSK Plc and Pfizer's consumer-health divisions. Pfizer had previously announced its intention to divest its stake in Haleon, with the recent sale being part of this ongoing process. The company had previously sold shares in January, raising £2.5 billion through a block trade. Similarly, GSK had also reduced its holdings in Haleon, completing its disengagement from the consumer health company the previous year.

Despite concerns from other European companies regarding potential US tariffs, Haleon remains confident in its low exposure to such impacts. The latest share sale is part of a trend in the European market, where shareholders are monetizing their long-held positions due to volatility and high stock prices. The transaction was led by Bank of America Corp., Citigroup Inc., and Goldman Sachs Group Inc.